Trademark: 90459471
Word
EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.
Status Date
Friday, May 31, 2024
Filing Date
Monday, January 11, 2021
Published for Opposition
Tuesday, September 7, 2021
42 Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services
Jan 14, 2021
New Application Entered
Apr 11, 2021
New Application Office Supplied Data Entered
Jul 20, 2021
Assigned To Examiner
Jul 28, 2021
Examiner's Amendment Entered
Jul 28, 2021
Examiners Amendment -Written
Jul 28, 2021
Examiners Amendment E-Mailed
Jul 28, 2021
Notification Of Examiners Amendment E-Mailed
Sep 7, 2021
Published For Opposition
Aug 2, 2021
Approved For Pub - Principal Register
Aug 18, 2021
Notification Of Notice Of Publication E-Mailed
Sep 7, 2021
Official Gazette Publication Confirmation E-Mailed
May 2, 2022
Sou Teas Extension Received
Nov 2, 2021
Noa E-Mailed - Sou Required From Applicant
May 4, 2022
Notice Of Approval Of Extension Request E-Mailed
May 2, 2022
Sou Extension 1 Filed
May 2, 2022
Sou Extension 1 Granted
Nov 2, 2022
Sou Teas Extension Received
Nov 2, 2022
Sou Extension 2 Filed
Nov 2, 2022
Sou Extension 2 Granted
Nov 4, 2022
Notice Of Approval Of Extension Request E-Mailed
May 1, 2023
Sou Teas Extension Received
May 1, 2023
Sou Extension 3 Filed
May 1, 2023
Sou Extension 3 Granted
May 3, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 2, 2023
Sou Teas Extension Received
Nov 2, 2023
Sou Extension 4 Filed
Nov 2, 2023
Sou Extension 4 Granted
Nov 4, 2023
Notice Of Approval Of Extension Request E-Mailed
Apr 30, 2024
Teas Statement Of Use Received
May 28, 2024
Case Assigned To Intent To Use Paralegal
May 30, 2024
Statement Of Use Processing Complete
May 31, 2024
Allowed Principal Register - Sou Accepted
May 31, 2024
Notice Of Acceptance Of Statement Of Use E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
